Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Pierobon

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Pancreas|July 4, 2019
Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic CarcinogenesisSandeep Nadella, Julian Burks, Matthew Huber, et al.
Ecohealth|February 27, 2016
Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and ResponseKathryn H Jacobsen, A Alonso Aguirre, Charles L Bailey, et al.
Cancer Research Communications|July 9, 2026
Acquisition of resistance to RAS inhibition is associated with the upregulation of macropinocytosis through both PI3K-dependent and -independent signalingRyan Robb, Sarah E Ackermann, Seamus E Degan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerRyan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.
Breast Cancer Research and Treatment|September 12, 2014
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancerGayle S Jameson, Emanuel F Petricoin, Jasgit Sachdev, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Neuro-Oncology|August 22, 2019
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clonesBen Yi Tew, Christophe Legendre, Mark A Schroeder, et al.
Science Signaling|December 19, 2023
RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signalingAntje Schaefer, Richard G Hodge, Haisheng Zhang, et al.
Cancer Cell|January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth SuppressionTikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2017
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast CancerMariaelena Pierobon, Corinne Ramos, Shukmei Wong, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Pancreas|July 4, 2019
Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic CarcinogenesisSandeep Nadella, Julian Burks, Matthew Huber, et al.
Ecohealth|February 27, 2016
Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and ResponseKathryn H Jacobsen, A Alonso Aguirre, Charles L Bailey, et al.
Cancer Research Communications|July 9, 2026
Acquisition of resistance to RAS inhibition is associated with the upregulation of macropinocytosis through both PI3K-dependent and -independent signalingRyan Robb, Sarah E Ackermann, Seamus E Degan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerRyan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.
Breast Cancer Research and Treatment|September 12, 2014
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancerGayle S Jameson, Emanuel F Petricoin, Jasgit Sachdev, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Neuro-Oncology|August 22, 2019
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clonesBen Yi Tew, Christophe Legendre, Mark A Schroeder, et al.
Science Signaling|December 19, 2023
RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signalingAntje Schaefer, Richard G Hodge, Haisheng Zhang, et al.
Cancer Cell|January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth SuppressionTikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2017
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast CancerMariaelena Pierobon, Corinne Ramos, Shukmei Wong, et al.
Pageof 10